Appointment dossier — Ovarian Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Cancer
- Olaparib — Human evidence · 3 positive · PMID 37592269, 33743851, 30345884, 39013199
- Bevacizumab — Human evidence · 2 positive / 2 negative-mixed · PMID 38872480, 22529265, 39013199, 36603894
- Mirvetuximab Soravtansine — Human evidence · 2 positive / 2 negative-mixed · PMID 40508029, 29232465, 39631181, 30379722
- Relacorilant — Human evidence · 2 positive / 1 negative-mixed · PMID 42334771, 40473448, 39032926, 37364223
- Rucaparib — Human evidence · 2 positive / 1 negative-mixed · PMID 41741111, 28057616, 39266137, 39013199
- Cisplatin — Human evidence · 1 positive / 2 negative-mixed · PMID 39549720, 41495830, 39013199, 22330607
- Paclitaxel — Human evidence · 1 positive / 2 negative-mixed · PMID 37592269, 40010134, 39013199, 22591426
- Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
- Carboplatin — Review evidence · 1 positive · PMID 37592269, 39013199
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Genistein — Review evidence · 1 positive · PMID 42133114
- Anastrozole — Review evidence · 0 positive · PMID 39013199
- Docetaxel — Review evidence · 0 positive · PMID 39013199
- Gemcitabine — Review evidence · 0 positive · PMID 39013199, 33917230
- Irinotecan — Review evidence · 0 positive / 1 negative-mixed · PMID 22330607
- Liposomal Doxorubicin — Review evidence · 0 positive · PMID 39013199
- Niraparib †Rx — Review evidence · 0 positive · PMID 39013199
- Tamoxifen — Review evidence · 0 positive · PMID 39013199
- Topotecan — Review evidence · 0 positive · PMID 39013199
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05606692 · Phase 4 — Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) (Taiwan)
- NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
- NCT06710756 · Phase 1 / Phase 2 — Lead-212 PSV359 Therapy for Patients With Solid Tumors (United States)
- NCT07067255 · Phase 1 / Phase 2 — Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer (China)
- NCT06395844 · Phase 1 / Phase 2 — Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer (China)
- NCT07760012 — 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors (China)
- NCT07403630 — INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) (Italy)
- NCT06564428 — A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration (China)
- NCT04251052 — A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (United States)
- NCT03958240 — Deciphering Mechanisms Underlying Cancer Immunogenicity (France)
- NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) (China)
- NCT04997096 — Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy (United States)
- NCT06640348 — Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer (China)
- NCT03954171 — Platino-resistance in Ovarian Cancer (France)
- NCT07532434 — A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer (China)
- NCT05349227 — Comprehensive Outcomes for After Cancer Health (United States)
- NCT05515354 · Phase 4 — Smoking Cessation and Menstrual Cycle Phase (Canada)
- NCT07339930 — Phenotyping of Patients With Polycystic Ovary Syndrome (France)
Most-relevant first: trials that name Ovarian Cancer, then broader trials you may still qualify for. 779 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Niraparib †Rx × CYP1A2 inhibitors (high-stakes) — Monitor (low)
- Niraparib †Rx × P-gp substrates (high-stakes) — Monitor (low)
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Niraparib †Rx × Bevacizumab — Synergize (low)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Olaparib has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Bevacizumab has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- I've read that Mirvetuximab Soravtansine has been studied in people for Ovarian Cancer — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05606692), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?